KabiCare
Patient support from Fresenius Kabi

TYENNE® (tocilizumab-aazg) Enrollment and Prescription Form

Required fields are marked with an asterisk (*).

1. Fax to KabiCare at 1-833-671-1010
2. Upload completed form file to kabicare.trialcard.com
3. Fax to patient's preferred specialty pharmacy
   Questions? Call 1.833.KABICARE (1-833-522-4227)

1 Patient Information - To be completed by a patient or legally authorized person. Please print clearly.

First Name*: _____ Last Name*: _____ D.O.B.*: ___/___/_____ Gender: ☐ M ☐ F

Address*: _____ City*: _____ State*: _____ Zip Code*: _____

Phone Number*: _____ ☐ Home ☐ Cell Email*: _____ Interpretation services needed: ☐ Y ☐ N

Parent/Guardian Name (if applicable): _____ Caregiver Name (if applicable): _____ Language: _____

Best time to call (Monday-Friday): ☐ Anytime ☐ Morning ☐ Afternoon ☐ Evening ☐ Check for permission to leave messages with caregiver

When did you start on treatment?*: ☐ Not yet started ☐ 0-3 months ago ☐ 4-6 months ago ☐ 7-12 months ago ☐ 12+ months ago

Required Patient Authorization and Additional Consents* (all fields must be completed prior to submitting to avoid delay in enrollment)

☐ I have read and agree to the terms and conditions provided, including the Patient Authorization to Share Personal Health Information (Section 1), the Copay Program Terms and Conditions (Section 3), the Bridge to Commercial Coverage (Section 4), the Fair Credit Reporting Act Authorization (Section 5), and/or PAP (Section 7). I understand that agreeing to these terms does not mean I am automatically enrolled in every program.

☐ I have read and agree to receive text messages and calls as explained in the Telephone Consumer Protection Act (TCPA) Consent (Section 2).

Patient or authorized representative signature: _____ Date of signature: ___/___/_____

If authorized representative signature, explain authority to act on behalf of patient: _____

2 Patient's Insurance Information - Provide copies of the front and back of all medical and prescription insurance cards.

Beneficiary/Cardholder Name: _____ Prescription Insurance: _____

Medical Insurance: _____ Rx Group #: _____ Rx ID #: _____

Medical Insurance ID #: _____ Group #: _____ Rx Bin #: _____ Rx PCN #: _____

☐ Commercial ☐ Medicare/ Medicaid ☐ VA ☐ Uninsured

▼ FOR HEALTH CARE PROVIDERS ONLY ▼

3

Prescriber's Name (First, Last)*: _____ Prescriber's Address: _____

Office Phone: _____ Contact Name: _____ City: _____ State: _____ Zip Code: _____

Contact Email: _____ Office Fax*: _____ Tax ID: _____ PTAN*: _____

Provider NPI #*: _____ SOC/Infusion Center: _____ Specialty: ☐ Rheumatology ☐ Other

Clinical Information

4

Diagnosis Date: ___/___/_____ Concomitant Medications: _____

Prior Therapies: _____ Drug Allergies: _____

Check all indications that apply†:

☐ Rheumatoid arthritis
☐ Polyarticular juvenile idiopathic arthritis in patients 2 years of age and older
☐ Giant cell arteritis
☐ Systemic juvenile idiopathic arthritis in patients 2 years of age and older

Primary ICD-10 code*: _____

† Cytokine release syndrome and coronavirus disease 19 indications do not apply to this program.

Pharmacy Prescription - Select medication, fill out and sign corresponding prescription below.

5

Patient's preferred specialty pharmacy: _____

Patient's Therapy

Patient's weight: _____ kg

IV Dosing Guidance:

Adult Rheumatoid Arthritis (RA):
- Initial 4 mg per kg every 4 weeks
- Increase to 8 mg per kg every 4 weeks based on clinical response

Giant Cell Arteritis (GCA):
- 6 mg per kg every 4 weeks in combination with a tapering course of glucocorticoids

Polyarticular Juvenile Idiopathic Arthritis (PJIA):
- <30 kg: 10 mg per kg every 4 weeks
- ≥30 kg: 8 mg per kg every 4 weeks

Systemic Juvenile Idiopathic Arthritis (SJIA):
- <30 kg: 12 mg per kg every 2 weeks
- ≥30 kg: 8 mg per kg every 2 weeks

☐ **TYENNE® intravenous (IV) infusion**

SIG: Infuse: _____ mg

Choose frequency:
☐ Once every 2 weeks
☐ Once every 4 weeks
☐ Other: _____

Subcutaneous Dosing Guidance:

Adult Rheumatoid Arthritis (RA):
- <100 kg: 162 mg administered subcutaneously every other week, followed by an increase to every week based on clinical response
- ≥100kg: 162 mg administered subcutaneously every week

Giant Cell Arteritis (GCA):
- 162 mg given once every week as a subcutaneous injection, in combination with a tapering course of glucocorticoids

Polyarticular Juvenile Idiopathic Arthritis (PJIA):
- <30 kg: 162 mg once every three weeks
- ≥30 kg: 162 mg once every two weeks

Systemic Juvenile Idiopathic Arthritis (SJIA):
- <30 kg: 162 mg every two weeks
- ≥30 kg: 162 mg every week

☐ **TYENNE® subcutaneous (SC) self-injectable**

☐ Prefilled syringe ☐ Autoinjector **Inject 162 mg**

Choose frequency:
☐ Once a week
☐ Once every 2 weeks
☐ Other: _____

Dispense:
☐ 1 month
☐ 2 months
☐ 3 months

Dispense TYENNE® vials: ☐ 80-mg dose ☐ 200-mg dose ☐ 400-mg dose

Refill: _____ times

PRESCRIBER CERTIFICATION: I certify that the above therapy is medically necessary and that the information provided is accurate to the best of my knowledge. I certify that I am the prescriber who has prescribed TYENNE to the previously identified patient and that I provided the patient with a description of the KabiCare patient support program. I authorize KabiCare to act on my behalf for the purposes of transmitting this prescription to the appropriate pharmacy designated by the patient utilizing their benefit plan (if applicable).

Prescriber's Signature (REQUIRED – Please print and sign the form)*: _____ **Date*:** ____/____/_____

IMPORTANT INFORMATION: By submitting this form you are referring the above patient to Fresenius Kabi's patient support program to determine eligibility and receive support related to a Fresenius Kabi product. Fresenius Kabi, its affiliates, collaborators and agents will use the information collected about you and your patient to provide the patient support and perform research and analytics on a de-identified basis, for management of the program. For more information about the categories of personal information collected by Fresenius Kabi and the purposes for which Fresenius Kabi uses personal information, visit www.fresenius-kabi.com/privacy-statement. Please share this information with your patient.

Please see Important Safety Information on the next page as well as click to see Full Prescribing Information, including **Boxed Warning** for TYENNE® (tocilizumab-aazg).

FRESENIUS KABI

KabiCare
Patient support from Fresenius Kabi

TYENNE® (tocilizumab-aazg) Enrollment and Prescription Form

1. Fax to KabiCare at 1-833-671-1010
2. Upload completed form file to kabicare.trialcard.com
3. Fax to patient's preferred specialty pharmacy
   Questions? Call 1.833.KABICARE (1-833-522-4227)

IMPORTANT SAFETY INFORMATION

RISK OF SERIOUS INFECTIONS:

Patients treated with TYENNE are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt TYENNE until the infection is controlled.

Reported infections include:

- **Active tuberculosis, which may present with pulmonary or extrapulmonary disease. Patients, except those with COVID-19, should be tested for latent tuberculosis before TYENNE use and during therapy (except patients with COVID-19). Treatment for latent infection should be initiated prior to TYENNE use.**
- **Invasive fungal infections, including candidiasis, aspergillosis, and pneumocystis. Patients with invasive fungal infections may present with disseminated, rather than localized, disease.**
- **Bacterial, viral and other infections due to opportunistic pathogens.**

The risks and benefits of treatment with TYENNE should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with TYENNE, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

CONTRAINDICATIONS

Known hypersensitivity to Tocilizumab products.

WARNINGS AND PRECAUTIONS

COVID-19

Monitor for signs and symptoms of new infections during and after treatment with TYENNE in patients with COVID-19. Limited information is available regarding the use of TYENNE in patients with COVID-19 and concomitant serious active infections. The risks and benefits of treatment with TYENNE in patients with COVID-19 and other concurrent infections should be considered.

Gastrointestinal Perforations

Events of gastrointestinal (GI) perforation have been reported in clinical trials, primarily as complications of diverticulitis in RA patients. Use TYENNE with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with new-onset abdominal symptoms for early identification of GI perforation.

Hepatotoxicity

Serious cases of hepatic injury have been observed in patients taking intravenous or subcutaneous Tocilizumab. Some of these cases have

resulted in liver transplant or death. Time to onset for cases ranged from months to years after treatment initiation. Most cases presented with marked elevations of transaminases (> 5 times ULN), and some cases presented with signs or symptoms of liver dysfunction and only mildly elevated transaminases.

Treatment with Tocilizumab was associated with a higher incidence of transaminase elevations; increased frequency and magnitude of these elevations were observed when Tocilizumab was used in combination with potentially hepatotoxic drugs (e.g., methotrexate).

It is not recommended to initiate TYENNE treatment in RA, GCA, PJIA, and SJIA patients with elevated transaminases ALT or AST greater than 1.5x ULN. In patients who develop elevated ALT or AST greater than 5x ULN discontinue TYENNE.

Patients who are hospitalized with COVID-19 may have elevated AST
or ALT levels. Multi-organ failure with involvement of the liver is recognized as a complication of severe COVID-19. The decision to administer TYENNE should balance the potential risks of acute treatment with TYENNE against the potential benefit of treating COVID-19. It is not recommended to initiate TYENNE treatment in COVID-19 patients with elevated ALT or AST above 10x ULN. Monitor ALT and AST during treatment.

Measure liver tests promptly in patients who report symptoms that may indicate liver injury. If the patient is found to have abnormal liver tests, TYENNE treatment should be interrupted. TYENNE should only be restarted in patients with another explanation for the liver test abnormalities after normalization of the liver tests.

Laboratory Parameters

Laboratory monitoring is recommended due to potential consequences of treatment-related laboratory abnormalities in neutrophils, platelets, lipids, and liver function tests. Dosage modifications may be required.

Neutropenia: Treatment with Tocilizumab was associated with a higher incidence of neutropenia. It is not recommended to initiate TYENNE treatment in RA, GCA, PJIA, and SJIA patients with a low neutrophil count i.e., absolute neutrophil count (ANC) less than 2000 per mm^3. In patients who develop an ANC less than 500 per mm^3 treatment is not recommended.

It is not recommended to initiate TYENNE treatment in COVID-19 patients with an ANC less than 1000 per mm^3. Neutrophils should be monitored.

Thrombocytopenia: Treatment with Tocilizumab was associated with a reduction in platelet counts. It is not recommended to initiate TYENNE in RA, GCA, PJIA, and SJIA patients with a platelet count below 100,000 per mm^3. In patients who develop a platelet count less than 50000 per mm^3, treatment is not recommended.

It is not recommended to initiate TYENNE treatment in COVID-19 patients with a platelet count less than 50000 per mm^3. Platelets should be monitored.

Elevated Liver Enzymes: It is not recommended to initiate TYENNE treatment in patients with elevated transaminases ALT or AST >1.5x ULN. In patients who develop elevated ALT or AST >5x ULN, treatment is not recommended.

Lipid Abnormalities: Treatment with Tocilizumab was associated with increases in lipid parameters such as total cholesterol, triglycerides, LDL cholesterols, and/or HDL cholesterol.

Immunosuppression

The impact of treatment with Tocilizumab on the development of malignancies is not known, but malignancies were observed in clinical studies with Tocilizumab. TYENNE is an immunosuppressant, and treatment with immunosuppressants may result in an increased risk of malignancies.

Hypersensitivity Reactions

Hypersensitivity reactions, including anaphylaxis, have been reported in association with Tocilizumab and anaphylactic events with a fatal outcome have been reported with intravenous infusion of Tocilizumab. Additionally, serious cutaneous reactions, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), have been reported in patients with autoinflammatory conditions treated with Tocilizumab products. TYENNE for intravenous use should only be infused by a healthcare professional with appropriate medical support to manage anaphylaxis. For TYENNE subcutaneous injection, advise patients to seek immediate medical attention if they experience any symptoms of a hypersensitivity reaction. If anaphylaxis or other hypersensitivity reaction occurs, stop administration of TYENNE immediately and discontinue TYENNE permanently. Do not administer TYENNE to patients with known hypersensitivity to TYENNE.

Demyelinating Disorders

The impact of treatment with Tocilizumab on demyelinating disorders is not known, but multiple sclerosis and chronic inflammatory demyelinating polyneuropathy were reported rarely in clinical studies. Monitor patients for signs and symptoms of demyelinating disorders. Prescribers should exercise caution in considering the use of TYENNE in patients with preexisting or recent-onset demyelinating disorders.

Active Hepatic Disease and Hepatic Impairment

Treatment with TYENNE is not recommended in patients with active hepatic disease or hepatic impairment.

Vaccinations

Avoid use of live vaccines concurrently with TYENNE. No data are available on the secondary transmission of infection from persons receiving live vaccines to patients receiving TYENNE or on the effectiveness of vaccination in patients receiving TYENNE. Patients should be brought up to date on all recommended vaccinations prior to initiation of TYENNE therapy, if possible.

ADVERSE REACTIONS

Most common adverse reactions (incidence of at least 5%): upper respiratory tract infections, nasopharyngitis, headache, hypertension, increased ALT, injection site reactions.

DRUG INTERACTIONS

In GCA patients, no effect of concomitant corticosteroid on Tocilizumab exposure was observed.

Cytochrome P450s in the liver are down-regulated by infection and inflammation stimuli including cytokines such as IL-6. Inhibition of IL-6 signaling in RA patients treated with TYENNE may restore CYP450 activities to higher levels than those in the absence of TYENNE leading to increased metabolism of drugs that are CYP450 substrates.

Exercise caution when co-administering TYENNE with CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral contraceptives, lovastatin, atorvastatin, etc.

USE IN PREGNANCY

The limited available data with Tocilizumab products in pregnant women are not sufficient to determine whether there is a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Fresenius Kabi at (800) 551-7176.

INDICATIONS

TYENNE is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs).

TYENNE is indicated for the treatment of giant cell arteritis (GCA) in adult patients.

TYENNE is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) in patients 2 years of age and older.

TYENNE is indicated for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.

TYENNE is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome in adults and pediatric patients 2 years of age and older.

TYENNE is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adult patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).

Please see Full Prescribing Information, including **Boxed Warning** for TYENNE® (tocilizumab-aazg).

FRESENIUS KABI

KabiCare
Patient support from Fresenius Kabi

TYENNE® (tocilizumab-aazg) Enrollment and Prescription Form

1. Fax to KabiCare at 1-833-671-1010
2. Upload completed form file to kabicare.trialcard.com
3. Fax to patient's preferred specialty pharmacy
   Questions? Call 1.833.KABICARE (1-833-522-4227)

ADDITIONAL TERMS AND CONDITIONS FOR ENROLLMENT

Section 1: Patient Authorization for the Use and Disclosure of Protected Health Information

PATIENT AUTHORIZATION AND RELEASE TO COLLECT, USE, AND DISCLOSE HEALTH INFORMATION

By my signature above, I agree to allow my clinicians, pharmacies, specialty pharmacy(ies), and health insurers (collectively "Healthcare Providers"), to use and disclose my personal information, including my protected health information (as such term is defined in the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") and regulations thereunder) related to this enrollment and prescription form or my use or potential use of TYENNE to Fresenius Kabi and its agents, authorized representatives, and contractors, including, without limitation, its HUB provider and third parties responsible for the administration of the KabiCare Patient Support Program, as further described below.

Information to Be Disclosed: My protected health information, as well as other state and/or federally protected personal information, including my personal contact and other demographic information, all medical records and financial information, and information relating to my treatment, the coordination of my treatment, and the delivery, packaging, and receipt of certain medication prescribed to me (collectively, my "Information"). Fresenius Kabi may de-identify my Information and such de-identified data will not be subject to this Authorization.

Persons to Whom My Information May Be Disclosed: Fresenius Kabi and the KabiCare Patient Support Program, including any third parties responsible for the administration of the KabiCare Patient Support Program and Fresenius Kabi's HUB provider.

Purposes for Which the Disclosures Are to Be Made: Disclosures of my Information may be made to KabiCare Patient Support Program so that KabiCare Patient Support Program may use and disclose my Information for purposes of:

1) Communicating with my Healthcare Providers about my prescription and medical condition, including to facilitate the order, fulfillment and delivery of my prescription as needed.
2) Establishing my eligibility for benefits from my health plan or other programs;
3) Contacting my insurer on my behalf to determine if I am eligible for health insurance coverage or other funds;
4) Providing appropriate product and reimbursement support;
5) Contacting me regarding case management and/ or educational information or training offered by or through the KabiCare Patient Support Program;
6) Contacting me regarding this Authorization or my use or potential use of my prescriptions and providing me with related communications, including through messages left for me that disclose that I take or may take certain prescription medications;
7) Contacting me to administer the KabiCare Patient Support Programs;
8) Administering, evaluating and improving the KabiCare Patient Support Programs, including performing research and analytics, analyzing the usage patterns and the effectiveness of services and helping to develop new products, services, and programs, and for other general business and administrative purposes; and
9) Disclosing my Information to third parties if required by law.

By signing this Authorization, I acknowledge my understanding that:

- I understand that I may refuse to sign this Authorization and that my refusal to sign this Authorization will not affect my right to treatment or payment of benefits for health care. However, I understand that if I refuse to sign, I will not be eligible to receive support through the KabiCare Patient Support Program.
- I have the right to revoke this Authorization at any time by calling KabiCare at 1-833-KABICARE (1-833-522-4227) or mailing 2250 Perimeter Park Dr., Suite 300 Morrisville, NC 27560. Revoking this Authorization will prohibit further uses and disclosures of my Information by the KabiCare Patient Support Program, except to the extent those uses and disclosures have been made in reliance on this Authorization and as permitted by applicable law.
- Certain pharmacy providers or other Healthcar
- Providers may receive remuneration for the use or disclosure of my Information, as permitted by this Authorization.
- Once my Information is released to KabiCare Patient Support Program based on this Authorization, my Information may not be subject to all of the protections and safeguards provided by HIPAA or other federal and state privacy laws. However, I understand that KabiCare Patient Support Program has agreed to use or disclose my Information received only for the purposes described in this Authorization or as required by law.
- This Authorization will remain in effect for a period of two (2) years after I sign it unless a shorter period is required by state law or is revoked by me earlier in writing.
- I am entitled to receive a copy of this signed Authorization.

The patient, or the patient's authorized representative, MUST sign this enrollment and prescription form to participate in the KabiCare Patient Support Program. My signature, signifying my agreement with this Authorization, is provided on page 1 of this enrollment and prescription form, where it states, 'I have read and agree to the Patient Authorization for the Use and Disclosure of Protected Health Information (section 1).' If an authorized representative signs for the patient, please indicate relationship to the patient.

Section 2: Telephone Consumer Protection Act (TCPA) Consent

By checking the second box in the "Required Patient Authorization and Additional Consents" section on page 1 of this enrollment and prescription form, you are agreeing to receive informational and marketing messages, including messages regarding products, health conditions, copay and financial assistance, from KabiCare and its third-party partners, including TrialCard Incorporated. You are providing consent that you can be contacted by phone or text messages through automatic telephone dialing systems under the guidelines of applicable law, such as the Telephone Consumer Protection Act at the phone number you provide. Message & data rates may apply. Message frequency varies. Text the word HELP in response to a text received from KabiCare or its partners for help. You may opt out of receiving text messages by texting the word STOP in response to a text received from KabiCare or its partners. The opt-out keyword STOP needs to be sent from the phone number where you want to stop receiving messages. If you have more than one phone number enrolled, you will need to follow this process with each phone number or contact 1-833-KabiCare (1-833-522-4227) for assistance. If your phone number changes, you should let KabiCare know right away to avoid your messages being sent to your old number. Ideally, you should follow the opt out process described above before you change your phone number. You will also need to let KabiCare know that it is ok to send you text messages to your new number. You may also opt out of communications from KabiCare or its partners entirely at any time by calling 1-833-KabiCare.

KabiCare will not sell or rent your personally identifiable information obtained as part of KabiCare's and its partners' text messaging communications with you and KabiCare does not permit its third-party suppliers, vendors, or contractors to sell any personally identifiable information obtained in the course of KabiCare's business relationship related to its text message communications with you. The information you provide as part of your consent to receive text messages will not be shared with any third parties other than KabiCare's partners and will only be used to document your consent to receive text messages, to send those text messages to you, and to comply with any applicable laws and regulations.

You understand that you are not required to agree to receive any phone calls or text messages as a condition of participation in the KabiCare Patient Support Program, and you may stop receiving text messages at any time by texting the word STOP in response to a text received from KabiCare or its partners.

Section 3: KabiCare Copay Assistance Program TERMS & CONDITIONS

To receive benefits under the Copay Assistance Program, the patient may contact the KabiCare Patient Support Program for current Program Product(s) subject to these Terms and Conditions. By participating in the Copay Assistance Program, patient acknowledges and agrees that he/she is eligible to participate and that he/she understands and agrees to comply with these Terms and Conditions.

- Patient must be prescribed the Program Product for an FDA-approved indication.
- Patient must have commercial (private or non-governmental) health insurance that provides coverage for the cost of the Program Product under a pharmacy or medical benefit plan. Uninsured and cash paying patients may be eligible for other types of support not part of the Copay Assistance Program.
- The Copay Assistance Program is valid for patients who have a valid prescription for a Fresenius Kabi medication and who are not reimbursed for the entire cost of the prescription by their commercial insurance plan. The Copay Assistance Program is not valid for patients enrolled in Medicaid, Medicare (including a Medicare Part D or Medicare Advantage plan, a Medigap plan, or an employer-sponsored health plan or prescription drug benefit program for Medicare-eligible retirees), Veteran Affairs health care programs, Department of Defense health care programs, TRICARE, CHAMPUS, Puerto Rico Government Health Insurance Plan , or any other state or federal medical or pharmaceutical benefit program or pharmaceutical assistance program, including any state pharmaceutical assistance programs (collectively, "Government Programs"). Patients who move from commercial insurance to Government Programs will no longer be eligible to participate in the Copay Assistance Program and agree to notify the Copay Assistance Program of any such change. If the patient lives in Massachusetts, the Copay Assistance Program expires on the earlier of: (i) the Expiration Date set forth below; (ii) the date an AB-rated generic equivalent becomes available for the Program Product; or (iii) January 31, 2026, absent a change in Massachusetts state law.
- If the patient lives in California, the Copay Assistance Program expires on the earlier of: (i) the Expiration Date set forth below; or (ii) the date an FDA approved therapeutically equivalent for the Program Product or over the counter product with the same active ingredients becomes available.
- Patients must have an out-of-pocket cost for the Program Product prior to the Expiration Date of the Copay Assistance Program.
- The benefit available under the Copay Assistance Program is limited to the amount the patient's private health insurance company indicates that the patient is obligated to pay for up to a per syringe/annual maximum.
- The Program may apply to patient out-of-pocket costs incurred for Program Product subject to per syringe/ annual maximums based on Program Product administration date. After reaching the maximum Copay Assistance Program benefit, the patient will be responsible for all remaining out-of-pocket expenses. The patient or provider may contact the KabiCare Patient Support Program for more information.
- The Patient and participating pharmacy or healthcare professional agree not to seek reimbursement for all, or any part, of the benefit received by the patient through the Copay Assistance Program. Participating patients and pharmacies or health care professionals are responsible for reporting receipt of Copay Assistance Program benefits as may be required by law.
- Patient must be a resident of the United States or the Commonwealth of Puerto Rico. Product must originate and be administered to patient in the United States or the Commonwealth of Puerto Rico.
- All information applicable to the Copay Assistance Program requested on the KabiCare.US site must be provided, and all certifications must be provided.
- No other purchase is necessary.
- The Copay Assistance Program is not insurance.
- It is illegal to sell, purchase, trade, counterfeit, or duplicate, or offer to sell, purchase, trade counterfeit, or duplicate the Copay Assistance Program card. Void if reproduced.
- The Copay Assistance Program is intended to comply with all applicable laws and regulations, including, without limitation, the federal Anti-Kickback Statute, its implementing regulations, and related guidance interpreting the federal Anti-Kickback Statute.
- The Copay Assistance Program is void where prohibited by law, taxed, or restricted. The Copay Assistance Program is not transferable. No substitutions are permitted.
- The Copay Assistance Program benefit has no cash value and cannot be combined with any other Copay Assistance Program, free trial, discount, rebate, prescription savings card, or other offer.
- The full value of the Copay Assistance Program benefit is intended to pass entirely to the patient. No other individual or entity is entitled to receive any discount or other amount in connection with the Copay Assistance Program.
- This offer is not conditioned on any past, present, or future purchase obligation, and the Copay Assistance Program does not obligate the use of any specific product or provider.
- To the extent applicable, this offer will be accepted only at participating pharmacies.
- KabiCare reserves the right to rescind, revoke, terminate, or amend the Copay Assistance Program at any time without notice.
- Data related to patient's receipt of Copay Assistance Program benefits may be collected, analyzed, and shared with KabiCare, for market research and other purposes related to assessing Copay Assistance Programs. Data shared with KabiCare will be aggregated and de-identified, meaning it will be combined with data related to other Copay Assistance Program redemptions and will not identify patient.
- The Terms and Conditions of the Copay Assistance Program are valid for Program Product only, and Fresenius Kabi reserves the right to rescind, revoke, or amend the Program without notice.

Section 4: Bridge to Commercial Coverage – Patient Attestation

KabiCare provides a limited and temporary supply of free product through the KabiCare Commercial Bridge Program ("Commercial Bridge Program") for eligible commercially insured patients when a prior authorization request has been pending with the payer for more than 7 days and when other program eligibility criteria have been satisfied.

The patient and participating providers may not seek reimbursement for any free product provided under the Commercial Bridge Program nor does the Commercial Bridge Program include payment for product administration fees.

By signing above, the patient hereby certifies to the following:

I certify that I am not enrolled in any Federal health care program (such as Medicare, Medicaid, Veteran Affairs health care programs, Department of Defense health care programs, TRICARE, or CHAMPUS). If I am enrolled in the Commercial Bridge Program, I certify that all information provided herein is correct and complete, to the best of my knowledge. I acknowledge that any product provided through the Commercial Bridge Program is provided on a complimentary basis. I certify that I will not submit or cause to be submitted any claims for payment or reimbursement for such products to any third-party payor, including any Federal health care programs. If I am or become in possession of such product, I understand that such product is only for me and I will not give such product to anyone else. I agree that I will not sell, trade, or distribute or otherwise transfer such product.

I understand that if I am enrolled in the Commercial Bridge Program, any future changes to prescription drug coverage, or insurance coverage may affect whether I can continue to participate in the Commercial Bridge Program. I agree to contact KabiCare at 1-833-KABICARE (1-833-522-4227) and tell them about any changes to my prescription drug coverage, or insurance coverage. I understand there is no purchase requirement associated with assistance through by or through the Commercial Bridge Program. I understand that completing this enrollment and prescription form does not guarantee that assistance will be provided.

Section 5: Fair Credit Reporting Act (FCRA) - Patient Authorization

The information I have provided is complete and accurate and will be used to decide if I am eligible to participate in the KabiCare Patient Assistance Program (the "PAP"). I agree that submitting my application is not a guarantee that I am entitled to participate in the PAP or that the PAP is obligated to provide me with any assistance. I understand that the PAP can revise, change, or terminate the program at any time. I authorize my healthcare providers and my health plan or insurers to give my medical and financial information to KabiCare, which administers the PAP on behalf of Fresenius Kabi, the distributor of the medicines, and to Experian, which assesses my income and ability to pay. I authorize KabiCare and its service providers to obtain credit reports about me from one or more credit reporting agencies in order to verify my information and determine my eligibility to participate in the PAP. I authorize KabiCare and Experian to review my medical and financial information and to use it only to determine if I am eligible to participate in the PAP, to operate the PAP, or as otherwise required or permitted by law. I understand and agree that KabiCare and Experian may contact me directly to verify the information I have submitted or to ask for additional information or documentation to process my application.

Section 6: Prescriber Certification and Statement of Medical Necessity

Prescriber Declaration: My signature certifies that the person named on this enrollment and prescription form is my patient, I will be supervising this patient's treatment, and the information that has been provided is complete and accurate to the best of my knowledge.

I also certify that I have made the clinical judgement that any products provided through KabiCare Patient Support Program(s), including KabiCare's Patient Assistance Program (the "PAP") are medically necessary and appropriate for the patient named on this enrollment and prescription form and will be used only by that patient. I will not use any such product or prescribe, provider, furnish, or dispense any portion thereof to any other person or patient. If I am or become in possession of such medications, I will not sell, resell, offer for sale, trade, or barter such products.

In addition, I certify that no claim for payment or reimbursement for any product furnished through KabiCare Patient Support Program(s), including the PAP, will be submitted to any third-party payer, including any Federal health care program (such as Medicare, Medicaid, Veteran Affairs health care programs, Department of Defense health care programs, TRICARE, or CHAMPUS), any other health care benefit plan, payer or patient, or returned for credit.

I further certify that (a) any reimbursement investigation support or assistance provided to patients through KabiCare Patient Support Program is not made in exchange, directly or indirectly, for any past, present, or future recommendation, prescription, purchase, or use of the above therapy or any other product or service for or from anyone and (b) my decision to prescribe product was based solely on my determination of medical necessity as set forth herein. I understand that completing this enrollment and prescription form does not guarantee that assistance will be provided to my patient.

Prescriber Acknowledgement: By submitting this enrollment and prescription form, I acknowledge that I am referring the patient named on this enrollment and prescription form to the KabiCare Patient Support Program(s), including the PAP. By submitting this enrollment and prescription form, I acknowledge and agree that Fresenius Kabi will collect, use, disclose and store personal information about me in accordance with its privacy policy, available at www.fresenius-kabi.com/privacy-statement.

Where required by applicable law, regulation, or other applicable authority, I have obtained appropriate written authorization from the patient ("Legal Permission") permitting me to use and disclose my patients' health, demographic, and other individually identifiable information, including insurance and financial information, to Fresenius Kabi, its affiliates, its program administrator, and their respective agents, authorized representatives, service providers and field reimbursement professionals for the purpose of assessing the patient's insurance coverage and eligibility for participation in the KabiCare Patient Support Program(s), providing the KabiCare Patient Support Program(s), copay assistance, patient assistance, and/or reimbursement support in connection with the patient's treatment with product. I maintain records of such Legal Permission consistent with applicable law.

I appoint KabiCare on my behalf, to convey this prescription to the appropriate dispensing entity, to the extent permitted under applicable state law. Special Note: Prescribers in all states must follow applicable laws for a valid prescription. For prescribers in states with official prescription form requirements, please submit an actual prescription along with this enrollment form.

Section 7: Patient Assistance Program - Patient Attestation

I certify that all information provided herein is correct and complete, to the best of my knowledge. To the extent I receive any free product through programs offered by or through the KabiCare Patient Support Programs, including the KabiCare Patient Assistance Program ("PAP"), I acknowledge that such product is provided on a complimentary basis. I certify that I will not submit or cause to be submitted any claims for payment or reimbursement for such products to any third-party payor, including any Federal health care programs (such as Medicare, Medicaid, Veteran Affairs health care programs, Department of Defense health care programs, TRICARE, or CHAMPUS). If I am or become in possession of such product, I understand that such product is only for me, and I will not give such product to anyone else. I agree that I will not sell, resell, offer for sale, trade, barter, distribute or otherwise transfer such product. I understand that if I am enrolled in a Medicare Part D Plan (including a Medicare Advantage Prescription Drug Plan) or other Federal health care program, I may not apply any assistance I receive to my "True Out of Pocket" ("TrOOP") expenditures, and that it is my responsibility to notify such Federal health care program(s) of any assistance I may receive, including my enrollment in the PAP. I understand that if I am enrolled in the PAP, any future changes to my income, prescription drug coverage, or insurance coverage may affect whether I can continue to participate in the PAP. I agree to contact KabiCare at 1-833-KABICARE (1-833-522-4227) and inform them about any changes to my income, prescription drug coverage, or insurance coverage. I understand there is no purchase requirement associated with assistance through by or through any KabiCare Patient Support Program(s), including the PAP.

I understand that Fresenius Kabi reserves the right at any time and without notice to me to modify and/or discontinue any or all support offered by or through KabiCare Patient Support Programs, including modification of eligibility criteria, covered medications and immediate termination of assistance provided through the PAP.

FRESENIUS KABI